Healthy Brain Aging Starts Here
.jpg?sfvrsn=460a2bb9_3 "Down Syndrome Research Participant")
Welcome to the Alzheimer's and Cognition Center
The Rocky Mountain Alzheimer's Disease Center (RMADC) has a new name! The Center is now called the University of Colorado Alzheimer's and Cognition Center (CUACC).
The new name reflects the broad reach of the Center, including innovative research and patient care. It better represents the work of more than 50 professionals affiliated with the CU Department of Neurology in two key places -- the Memory Disorders Clinic, in cooperation with the University of Colorado Hospital, and the University of Colorado Alzheimer's and Cognition Center research laboratories at the CU Anschutz Medical Campus.
While Alzheimer's disease is the most common and recognized cause of dementia, there are many other diseases and conditions that affect thinking and brain health. Adding the word "cognition" to our title encompasses the full breadth of our research and clinical expertise, including our focus on healthy brain aging.
Dr. Huntington Potter
Director
CU Alzheimer's and Cognition Center
Upcoming Events
-
24th Annual Center for African American Health’s Health Expo
| 09:00 AM - 02:00 PM
-
Colorado PCA Support Group
| 10:45 AM - 12:00 PM
-
AFTD Education Conference 2025
| All Day
-
More on Dementia: Family History, Genetics, Dementia & Alzheimer's
| 11:30 AM - 01:00 PM
-
Walk to End Alzheimer's 2025
| All Day
In the News
- CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies, GlobeNewswire, click here to read
- Why It's Hard for Patients to Get the Newest Alzheimer's Drugs, Verywell Health, click here to read
- Dementia with Lewy Bodies Has Been Difficult to Diagnose Early, But Comprehensive Cognitive Testing Could Change That, CU Anschutz Today, click here to read
- Donepezil Found Effective for Improving Memory After Traumatic Brain Injury, Psychiatric News, click here to read
- Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies, Cognition Therapeutics, click here to read
- Who's Paying for Those Blood-based Biomarker Tests for Alzheimer's Disease?, Neurology Today, click here to read
- Former DU Chancellor Rebecca Chopp reflects on living with Alzheimer’s, in 'Still Me', Rocky Mountain PBS, click here to read and watch
- Alzheimer's and genetics: A complicated relationship, UCHealth Today, click here to read
- How rheumatoid arthritis and Down syndrome are helping researchers find treatments for Alzheimer’s, CPR News, click here to read
- Clinical Trials hope to curb and reverse Alzheimer's Colorado Public Radio, Colorado Matters click here to listen
- ‘Game of Thrones’ Study Offers Insights Into a Little-Understood Brain Disorder Everyday Health, click here to read
- First patient at UCHealth receives new treatment for Alzheimer’s disease UCHealth Today, click here to read
- Alzheimer's Patients' Cognition Improves with Sargramostim (GM-CSF), New Study Shows. Prime Time News, click here to read
- Importance of White Matter by Dr. Christopher M. Filley. The Conversation, click here to read
- Interview with CUACC Expert on Aphasia. CU Anschutz Today, click here
- Groundbreaking research could improve cognition for people with Down Syndrome. Denver Channel 7, click here
- CU Anschutz Researchers Identify Drugs that Curb Alzheimer's Symptoms. CBS Colorado, click here
Clinical Trial Updates
- CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies, Press release here
- Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - Press release here
- Donanemab (Kisunla) approved by FDA on July 2, 2024 - Clinic Statement Here
- Leqembi (lecanemab) approved by FDA and CMS - Clinic Statement Here
- Alzheimer's Patients' Cognition Improves with sargramostim (GM-CSF), New CUACC Study Shows - Press Release Here; Paper Available Here
- EIP Pharma Announces Positive Phase 2 Results for Neflamapimod in Mild-to-Moderate Dementia with Lewy bodies (DLB) - Press Release Here
University of Colorado Systemwide Land Acknowledgement
October 28, 2020
Office of the President
As we gather, we honor and acknowledge that the University of Colorado’s four campuses are on the traditional territories and ancestral homelands of the Cheyenne, Arapaho, Ute, Apache, Comanche, Kiowa, Lakota, Pueblo and Shoshone Nations. Further, we acknowledge the 48 contemporary tribal nations historically tied to the lands that comprise what is now called Colorado.
Acknowledging that we live in the homelands of Indigenous peoples recognizes the original stewards of these lands and their legacies. With this land acknowledgment, we celebrate the many contributions of Native peoples to the fields of medicine, mathematics, government and military service, arts, literature, engineering and more. We also recognize the sophisticated and intricate knowledge systems Indigenous peoples have developed in relationship to their lands.
We recognize and affirm the ties these nations have to their traditional homelands and the many Indigenous people who thrive in this place, alive and strong. We also acknowledge the painful history of ill treatment and forced removal that has had a profoundly negative impact on Native nations.
We respect the many diverse Indigenous peoples still connected to this land. We honor them and thank the indigenous ancestors of this place. The University of Colorado pledges to provide educational opportunities for Native students, faculty and staff and advance our mission to understand the history and contemporary lives of Native peoples.
See the full statement from the CU President here.